The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

The global aspirin drug market is poised for substantial growth over the next decade, with its value expected to increase ...

Bayer's venerable testosterone replacement product ... Nubeqa is one of three drugs that the company is hoping will help it weather that impact on revenues, along with recently-approved diabetic ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic ...

The drug could become the first approved treatment option for women who suffer from hot flashes as they undergo adjuvant endocrine therapy - a treatment for breast cancer. Bayer is facing several ...

Additionally, the ophthalmology drug Eylea™ saw an 8.6% increase in sales. However, these positive developments were offset by a 23% decline in sales of Xarelto, which is Bayer's blockbuster ...

Bayer expects its pharmaceutical business to ... for symptoms of menopause — later this year. It hopes these new drugs will offset falling sales of its blockbuster blood thinner Xarelto, which ...

Ibuprofen (Advil or Motrin), naproxen (Aleve) and aspirin (Bayer or Ecotrin) are common pain relievers that belong to a class of medication called non-steroidal anti-inflammatory drugs (NSAIDs).